RegulatoryBusiness Standard
Caplin Point slides 13% after US FDA flags plant
Negative-99
GreyOak summary
Caplin Point Laboratories shares fell 13.23% over three sessions after the US FDA classified its Gummidipoondi facility as Official Action Indicated (OAI). The FDA cited 10 procedural observations from an unannounced inspection. The company stated there is no material impact on its financials or operations.
What it affects
- Caplin Point LaboratoriesCAPLIPOINTNegative -99
Stock fell 13% after FDA flagged facility.Rolling sentiment Negative -63
Source
Read the original at Business StandardMore Caplin Point Laboratories news
- Caplin Point shares decline after USFDA OAI classificationCNBC-TV18 · Regulatory ·
- Caplin Point US own-label sales to double by 2026-27CNBC-TV18 · Company update ·
- Caplin Point Q2 revenue up 18%, stock falls 6%CNBC-TV18 · Results ·